Foundation Medicine to Collaborate with Eisai on International Oncology Clinical Trial

  Foundation Medicine to Collaborate with Eisai on International Oncology
  Clinical Trial

 Prospective genomic profiling of patients will help stratify enrollment and
                 provide insight for clinical trial outcomes

Business Wire

CAMBRIDGE, Mass. -- October 09, 2012

Foundation Medicine, Inc. announced today a multi-year collaboration with
Eisai Co., Ltd., Tokyo, Japan for genomic profiling and diagnostic discovery
in a multi-site, international clinical trial of an Eisai targeted therapeutic
candidate. The goal of the collaboration is to prospectively identify specific
genomic alterations in each patient’s tumor and use the results to inform
patient stratification, to guide drug development decisions and potentially
for the commercialization of new molecular diagnostics. Foundation Medicine
will receive an upfront payment and is eligible for future diagnostic rights.

“Eisai is dedicated to bringing new treatment options to cancer patients,”
said Takashi Owa, Ph.D., chief innovation officer, Eisai. “This collaboration
with Foundation Medicine, utilizing their depth of molecular oncology
knowledge and ability to partner on a global scale, will help Eisai better
understand the genomic makeup of each patient as we work to deliver new
targeted treatments that may benefit patients.”

“This collaboration represents the continued advancement of our partnership
strategy as we gain greater understanding into the key alterations driving
tumor growth,” said Michael J. Pellini, M.D., president and chief executive
officer, Foundation Medicine. “By using our comprehensive genomic profile to
inform trial enrollment and outcomes analysis, Eisai can reveal the genomic
drivers of an individual patient’s disease and may be able to more rapidly
advance effective targeted treatments for cancer.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a
transformation in cancer care in which treatment is informed by a deep
understanding of the genomic changes that contribute to each patient’s unique
cancer. The company’s initial clinical product, FoundationOne™, is a fully
informative genomic profile to identify a patient’s individual molecular
alterations and match them with relevant targeted therapies and clinical
trials. Foundation Medicine’s molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
healthcare system. For more information about Eisai, please visit


Foundation Medicine
Dan Budwick
Pure Communications, Inc.
Sheryl Seapy
Pure Communications, Inc.
Press spacebar to pause and continue. Press esc to stop.